Factors affecting cytochrome P-450 3A activity in cancer patients

被引:108
作者
Baker, SD
van Schaik, RHN
Rivory, LP
ten Tije, AJ
Dinh, K
Graveland, WJ
Schenk, PW
Charles, KA
Clarke, SJ
Carducci, MA
McGuire, WP
Dawkins, F
Gelderblom, H
Verweij, J
Sparreboom, A
机构
[1] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA
[2] Erasmus Univ, Med Ctr, Dept Clin Chem, Rotterdam, Netherlands
[3] Erasmus Univ, Med Ctr, Dept Biostat, Rotterdam, Netherlands
[4] Erasmus Univ, Med Ctr, Dept Med Oncol, Rotterdam, Netherlands
[5] Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia
[6] Univ Sydney, Dept Med Oncol, Sydney, NSW 2006, Australia
[7] Franklin Square Hosp Ctr, Baltimore, MD USA
[8] Howard Univ, Ctr Canc, Washington, DC 20059 USA
[9] Leiden Univ, Med Ctr, Leiden, Netherlands
[10] NCI, Clin Pharmacol Res Core, Bethesda, MD USA
关键词
D O I
10.1158/1078-0432.CCR-04-1371
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The purpose is to identify the demographic, physiologic, and inheritable factors that influence CYP3A activity in cancer patients. Experimental Design: A total of 134 patients (62 females; age range, 26 to 83 years) underwent the erythromycin breath test as a phenotyping probe of CYP3A. Genomic DNA was screened for six variants of suspected functional relevance in CYP3A4 (CYP3A4*1B, CYP3A4*6, CYP3A4*17, and CYP3A4*18) and CYP3A5 (CYP3A5*3C and CYP3A5*6). Results: CYP3A activity (AUC(0-40min)) varied up to 14-fold in this population. No variants in the CYP3A4 and CYP3A5 genes were a significant predictor of CYP3A activity (P > 0.2954). CYP3A activity was reduced by similar to50% in patients with concurrent elevations in liver transaminases and alkaline phosphatase or elevated total bilirubin (P < 0.001). In a multivariate analysis, CYP3A activity was not significantly influenced by age, sex, and body size measures (P > 0.05), but liver function combined with the concentration of the acute-phase reactant, alpha-1 acid glycoprotein, explained similar to18% of overall variation in CYP3A activity (P < 0.001). Conclusions: These data suggest that baseline demographic, physiologic, and chosen genetic polymorphisms have a minor impact on phenotypic CYP3A activity in patients with cancer. Consideration of additional factors, including the inflammation marker C-reactive protein, as well as concomitant use of other drugs, food constituents, and complementary and alternative medicine with inhibitory and inducible effects on CYP3A, is needed to reduce variation in CYP3A and treatment outcome to anticancer therapy.
引用
收藏
页码:8341 / 8350
页数:10
相关论文
共 66 条
  • [31] Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
    Kuehl, P
    Zhang, J
    Lin, Y
    Lamba, J
    Assem, M
    Schuetz, J
    Watkins, PB
    Daly, A
    Wrighton, SA
    Hall, SD
    Maurel, P
    Relling, M
    Brimer, C
    Yasuda, K
    Venkataramanan, R
    Strom, S
    Thummel, K
    Boguski, MS
    Schuetz, E
    [J]. NATURE GENETICS, 2001, 27 (04) : 383 - 391
  • [32] Genetic contribution to variable human CYP3A-mediated metabolism
    Lamba, JK
    Lin, YS
    Schuetz, EG
    Thummel, KE
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (10) : 1271 - 1294
  • [33] Common allelic variants of cytochrome P4503A4 and their prevalence in different populations
    Lamba, JK
    Lin, YS
    Thummel, K
    Daly, A
    Watkins, PB
    Strom, S
    Zhang, J
    Schuetz, EG
    [J]. PHARMACOGENETICS, 2002, 12 (02): : 121 - 132
  • [34] Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups
    Lee, SJ
    Usmani, KA
    Chanas, B
    Ghanayem, B
    Xi, T
    Hodgson, E
    Mohrenweiser, HW
    Goldstein, JA
    [J]. PHARMACOGENETICS, 2003, 13 (08): : 461 - 472
  • [35] Mathijssen RHJ, 2002, J NATL CANCER I, V94, P1247, DOI 10.1093/jnci/94.16.1247
  • [36] Now important are gender differences in pharmacokinetics?
    Meibohm, B
    Beierle, I
    Derendorf, H
    [J]. CLINICAL PHARMACOKINETICS, 2002, 41 (05) : 329 - 342
  • [37] SIMPLIFIED CALCULATION OF BODY-SURFACE AREA
    MOSTELLER, RD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (17) : 1098 - 1098
  • [38] Paris PL, 1999, CANCER EPIDEM BIOMAR, V8, P901
  • [39] Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology
    Richardson, MA
    Sanders, T
    Palmer, JL
    Greisinger, A
    Singletary, SE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (13) : 2505 - 2514
  • [40] Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response
    Rivory, LP
    Slaviero, KA
    Clarke, SJ
    [J]. BRITISH JOURNAL OF CANCER, 2002, 87 (03) : 277 - 280